PD-3 Impact of RAS status, prior targeted therapy, age, and gender on the activity of aflibercept plus FOLFIRI in patients with metastatic colorectal cancer: Real-world data from the QoLiTrap study
Titel:
PD-3 Impact of RAS status, prior targeted therapy, age, and gender on the activity of aflibercept plus FOLFIRI in patients with metastatic colorectal cancer: Real-world data from the QoLiTrap study
Auteur:
von Moos, R. Thaler, J. Kröning, H. Zahn, M. Scholten, F. Pederiva, S. Anchisi, S. Bohanes, P. Grünberger, B. Windemuth-Kieselbach, C. Piringer, G. Hofheinz, R.